ArticleJournal of the Society for Cardiovascular Angiography & Interventions2025
Lithotripsy-Facilitated or Conventional Percutaneous Mitral Balloon Valvuloplasty for Calcific Mitral Valve Disease: A Systematic Review.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Emerging Role of Lithotripsy in Structural Heart Interventions.Current cardiology reports · 2025Review
- Back to the Future: Reviving Old Concepts to Advance Transcatheter Treatment of Calcific Mitral Valve Disease.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of percutaneous mitral balloon valvuloplasty (PMBV) for mitral stenosis (MS) secondary to mitral annular calcification (MAC) is poorly understood. The purpose of this systematic review was to consolidate existing data on conventional and lithotripsy-facilitated PMBV in patients with calcific mitral valve disease, to better understand procedural outcomes. Methods: We performed a systematic search of the literature published in PubMed and Scopus databases through May 2024. We included all studies that reported outcomes of conventional PMBV as a standalone therapy or lithotripsy-facilitated mitral intervention for calcific mitral valve disease. Results: A total of 12 reports met the criteria for inclusion (8 lithotripsy and 4 conventional PMBV), including 4 case series and 8 case reports. Conventional PMBV (n = 44) procedural success in MAC was variable and associated with a limited reduction in mitral gradient in most patients. After conventional PMBV, 4 (9.1%) patients had moderate-to-severe mitral regurgitation (MR) or more, and 6 (13.6%) required mitral re-intervention. On the contrary, lithotripsy-facilitated PMBV for MAC (n = 40) led to hemodynamic improvement in most cases with a mean reduction of 5 to 8 mm Hg in mean mitral gradient. One case (2.5%) developed increased MR from baseline, and 1 (2.5%) required mitral reintervention. Outcomes beyond 3 months were lacking and precluded assessment on whether these improvements are sustained. Conclusions: This systematic review suggests that lithotripsy-facilitated PMBV for MAC-related MS is feasible and may offer favorable short-term outcomes compared with conventional PMBV alone. These findings highlight the need for larger, multicenter studies with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.